XML 66 R55.htm IDEA: XBRL DOCUMENT
v3.21.2

Royalty Purchase Agreements - Viracta (Details) $ in Thousands |  | 9 Months Ended | 12 Months Ended
--- | --- | --- | ---
Mar. 22, 2021 USD ($) item | Sep. 30, 2021 USD ($) | Dec. 31, 2020 USD ($)
Agreements |  |  |
Payments to acquire milestones and royalties |  | $ 20,500 |
Long-term royalty receivables |  | 55,075 | $ 34,575
Impairment of long-term royalty receivable |  | 0 | $ 0
Viracta | Royalty Purchase Agreement [Member] |  |  |
Agreements |  |  |
Number of drug candidates | item | 2 |  |
Maximum amount of potential milestones and other payments receivable | $ 54,000 |  |
Amount of maximum consideration retained | 20,000 |  |
Maximum amount of potential regulatory and commercial milestones receivable | 57,000 |  |
Payments to acquire milestones and royalties | 13,500 |  |
Long-term royalty receivables | $ 13,500 |  |
Impairment of long-term royalty receivable |  | $ 0 |

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Number of drug candidates under the terms of the agreement. + References No definition available. + Details
Name: | xoma_AgreementDrugCandidatesNumber
Namespace Prefix: | xoma_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | instant

X
- Definition The aggregate amount of write-downs for impairments recognized during the period for long term royalty receivable assets. + References No definition available. + Details
Name: | xoma_ImpairmentOfLongTermRoyaltyReceivable
Namespace Prefix: | xoma_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Long-term royalty receivable non current. + References No definition available. + Details
Name: | xoma_LongTermRoyaltyReceivableNonCurrent
Namespace Prefix: | xoma_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Amount of maximum consideration retained by Company excluded from maximum potential milestones under terms of agreement. + References No definition available. + Details
Name: | xoma_MaximumConsiderationRetained
Namespace Prefix: | xoma_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Maximum amount of potential milestones and other payments receivable, excluding consideration retained by company under the terms of the agreement. Excludes regulatory and commercial milestones. + References No definition available. + Details
Name: | xoma_MilestonesReceivableExcludingConsiderationRetainedMaximum
Namespace Prefix: | xoma_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Payments related to purchase of royalty rights. + References No definition available. + Details
Name: | xoma_PaymentsRelatedToPurchaseOfRoyaltyRights
Namespace Prefix: | xoma_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Maximum amount of potential regulatory and commercial milestones receivable under the terms of the agreement. + References No definition available. + Details
Name: | xoma_RegulatoryAndCommercialMilestonesReceivableMaximum
Namespace Prefix: | xoma_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Details
Name: | srt_CounterpartyNameAxis=xoma_ViractaTherapeuticsInc.Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=xoma_RoyaltyPurchaseAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |